HSBC Holdings plc vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? HSBC Holdings plc trades at $92.78 (market cap $311.92B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.36 (market cap $2.27B). The key difference: HSBC Holdings plc is far larger — about 137.4× SELLAS Life Sciences Group Inc. Common Stock's market cap, and HSBC Holdings plc pays a 4.05% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals.
| HSBC | SLS | |
|---|---|---|
Market Cap | $311.92B | $2.27B |
Volume | 3,546,658 | 4,179,659 |
Sector | Financials | Health |
52-Week High | $107.86 | $15.46 |
52-Week Low | $65.67 | $1.39 |
Typical Hold Time | 36 Days | — |
Enterprise Value | $222.19B | $2.14B |
Dividend Yield | 4.05% | — |
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $93.71, down 3.97% today, with a bearish technical signal from moving averages and oscillators. The stock shows solid fundamentals with a P/E of 13.23, net income margin of 34.54%, and recent earnings beats in two of the last three quarters. Recent developments include expansion in technology banking and wealth management services, while analyst consensus leans toward Hold with 52.38% of ratings.
The outlook remains mixed with strong profitability metrics offset by bearish technical indicators and negative net cash flow. Key opportunities include wealth management growth and strategic hires, while risks involve CFO transition and competitive pressures. The stock's valuation appears reasonable but requires monitoring of cash flow trends and execution on growth initiatives.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →